Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 20/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6662981 | 0.88 | P2RX7 (0.71) | P2RX7 | |
| SCHEMBL5710443 | 0.86 | P2RX7 (0.75) | P2RX7 | |
| SCHEMBL5710583 | 0.85 | P2RX7 (0.68) | P2RX7 | |
| Hydrochloric Acid SCHEMBL5710644 | 0.85 | P2RX7 (0.70) | P2RX7 | |
| Hydrochloric Acid SCHEMBL5710531 | 0.84 | P2RX7 (0.67) | P2RX7 | |
| SCHEMBL5074755 | 0.84 | P2RX7 (0.73) | P2RX7 | |
| SCHEMBL5076164 | 0.84 | P2RX7 (0.69) | P2RX7 | |
| SCHEMBL5077420 | 0.84 | P2RX7 (0.66) | P2RX7 | |
| SCHEMBL5710475 | 0.83 | P2RX7 (0.68) | P2RX7 | |
| Hydrochloric Acid SCHEMBL5710669 | 0.83 | P2RX7 (0.72) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1448195-B1 | N-ADAMANTYLMETHYL DERIVATES AND INTERMEDIATES AS PHARMACEUTICAL COMPOSITIONS AND PROCESSES FOR THEIR PREPARATION | ASTRAZENECA AB (SE) | 2006-11-02 | — | — | EP | disclosed |
| US-7129246-B2 | N-adamantlmethyl derivatives and intermediates as pharmaceutical compositions and processes for their preparation | ASTRAZENECA AB (SE) | 2006-10-31 | — | — | US | disclosed |
| US-20050010052-A1 | N-adamantlmethyl derivatives and intermediates as pharmaceutical compositions and processes for their preparation | ASTRAZENECA AB (SE) | 2005-01-13 | — | — | US | disclosed |
| EP-1448195-A1 | N-ADAMANTYLMETHYL DERIVATES AND INTERMEDIATES AS PHARMACEUTICAL COMPOSITIONS AND PROCESSES FOR THEIR PREPARATION | AstraZeneca AB (SE) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003041707-A1 | N-ADAMANTYLMETHYL DERIVATES AND INTERMEDIATES AS PHARMACEUTICAL COMPOSITIONS AND PROCESSES FOR THEIR PREPARATION | ASTRAZENECA AB (SE) | 2003-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050010052-A1 | N-adamantlmethyl derivatives and intermediates as pharmaceutical compositions and processes for their preparation | ADRA1A, ADRA1D, ADORA1 | P2RX7 1517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.